Sivi Ouwerkerk-Mahadevan, PhD

Sivi Ouwerkerk studied Bio-Pharmaceutical Sciences at Leiden University, The Netherlands and received a Ph.D from the same University in 1997, on the subject of synthesis of inhibitors of glutathione conjugation. She has more than 15 years experience in pharmaceutical industry, and has worked in the preclinical DMPK departments at Solvay Pharmaceuticals in the Netherlands and  Eli Lilly and company in Belgium and Indianapolis. Seven years ago, Sivi Ouwerkerk joined the Clinical Pharmacology department at Johnson & Johnson as a Clinical Pharmacology Leader and worked in the fields of neuroscience, metabolic diseases and infectious diseases. She is currently Scientific Director, with as main responsibility the clinical development of drugs for the treatment of hepatitis C. Her main area of research interest is Physiologically Based Pharmacokinetic modelling (PBPK), and it’s application to the prediction of drug-interactions and pharmacokinetics in special populations.